|Year : 2022 | Volume
| Issue : 2 | Page : 204-206
Afatinib-induced acneiform eruptions
Twinkle Singh Thakur, Shreya Agrawal, Bhushan Madke, Sugat Jawade, Gauri Padmawar, Khushboo Verma
Department of Dermatology, Venereology and Leprosy, Jawaharlal Nehru Medical College, Datta Meghe Institute of Medical Sciences, Wardha, Maharashtra, India
|Date of Submission||01-Mar-2022|
|Date of Acceptance||05-Jul-2022|
|Date of Web Publication||23-Aug-2022|
Department of Dermatology, Venereology and Leprosy, Jawaharlal Nehru Medical College, Datta Meghe Institute of Medical Sciences, Wardha - 442 001, Maharashtra
Source of Support: None, Conflict of Interest: None
Epidermal growth factor receptor (EGFR) inhibitors are being increasingly used in the treatment of non-small cell carcinoma of the lung. Cutaneous toxicity of various EGFR inhibitors is being increasingly noticed by dermatologists. We hereby report a case of papulopustular eruption in a male patient who had received oral afatinib for well-differentiated squamous cell carcinoma of the lower lip. The offending drug was continued and the papulopustular eruption was treated with oral doxycycline and local care.
Keywords: Afatinib, papulopustular eruptions, skin toxicity
|How to cite this article:|
Thakur TS, Agrawal S, Madke B, Jawade S, Padmawar G, Verma K. Afatinib-induced acneiform eruptions. J Sci Soc 2022;49:204-6
| Introduction|| |
Afatinib is an irreversible, multi-receptor inhibitor mostly used in patients with non-small cell lung cancer (NSCLC), which shows epidermal growth factor receptor (EGFR) mutations. Vomiting, diarrhea, fatigue, and loss of appetite are the most common complications. Cutaneous manifestation is the second most commonly reported side effect.,,
| Case Report|| |
A 38-year-old male was referred to our department from the department of medical oncology in view of skin eruption over his face, upper back, and chest area for 10–12 days. The patient was a diagnosed case of squamous cell carcinoma of the lower lip along with cervical lymph node metastasis. He was treated with oral afatinib 40 mg once a day for the past 6 weeks as prescribed by an oncologist. The patient reported that the eruption started about 3 weeks of starting oral afatinib. There was no prior history of drug intake in the preceding 2 months except the drug, afatinib.
Cutaneous examination showed papulopustular eruption on his face [Figure 1] and [Figure 2], upper chest, and upper back. The patient reported that the eruption is associated with mild itching. The left angle of the lower lip showed well-defined firm to hard indurated growth [Figure 3]. Lymph node examination showed enlarged cervical lymph nodes. There were no other significant mucocutaneous findings in the patient. Based on the Naranjo Adverse Drug Reaction Probability Scale, we diagnosed our patient to be a definite case of afatinib-induced acneiform eruption.
|Figure 3: H and E-stained section showing a sterile neutrophilic follicular inflammation|
Click here to view
Biopsy from the growth showed features suggestive of keratinizing moderately well-differentiated squamous cell carcinoma of the lower lip. Fine-needle aspiration cytology from one of the enlarged lymph nodes showed features of metastatic squamous cell carcinoma. H and E staining from one of the pustular lesions showed inflammatory cells comprising neutrophils suggestive of sterile pustule [Figure 3]. Complete hemogram, serum biochemistry, and urinalysis were within normal reference range. Serology for hepatitis B, hepatitis C, and HIV was negative.
As per the Common Terminology Criteria for Adverse Events version 5.0, our patient was diagnosed with Grade 2 papulopustular eruptions and was treated with oral doxycycline (100 mg twice a day) and topical clindamycin phosphate (1%) gel to be applied at bedtime. The patient reported that there was a 50% reduction in the severity of the rash at the end of 1 month.
| Discussion|| |
Epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (EGFR-TKI) is the current standard of care treatment for advanced NSCLC with activating mutations of the EGFR gene. Afatinib is a widely used EGFR inhibitor in routine oncologic practice. However, the recent meta-analysis on its adverse events observed that the drug is associated with an 84.8% higher risk of developing skin rashes.
The higher incidences of exaggerated dermatological manifestations with afatinib could be explained by two reasons. First, afatinib, an irreversible EGFR-TKI, that exhibits a strong affinity to EGFR may result in greater skin inflammation. Second, synergistic effects could occur with dual inhibition of EGFR and ERBB2 (formerly HER2 or HER2/neu) by afatinib.,
We reported a case of papulopustular eruptions on a patient with a history of afatinib drug, A similar case presentation was recently reported in the USA in a 72-year-old man with a history of metastatic EGFR plus non-small cell lung carcinoma, which is in our case we observed the lesions in a much younger male age 38 years with a history of squamous cell carcinoma of the lower lip.
We treated the lesions with oral doxycycline and topical clindamycin gel as a palliative care and known regimen used in such lesions was well received by our patient.,
Declaration of patient consent
The authors certify that they have obtained all appropriate patient consent forms. In the form the patient(s) has/have given his/her/their consent for his/her/their images and other clinical information to be reported in the journal. The patients understand that their names and initials will not be published and due efforts will be made to conceal their identity, but anonymity cannot be guaranteed.
Financial support and sponsorship
Conflicts of interest
There are no conflicts of interest.
| References|| |
Park K, Tan EH, O'Byrne K, Zhang L, Boyer M, Mok T, et al.
Afatinib versus gefitinib as first-line treatment of patients with EGFR mutation-positive non-small-cell lung cancer (LUX-Lung 7): A phase 2B, open-label, randomised controlled trial. Lancet Oncol 2016;17:577-89.
Dungo RT, Keating GM. Afatinib: First global approval. Drugs 2013;73:1503-15.
Keating GM. Afatinib: A review of its use in the treatment of advanced non-small cell lung cancer. Drugs 2014;74:207-21.
Robijns J, Lodewijckx J, Claes S, Van Bever L, Pannekoeke L, Censabella S, et al
. Photobiomodulation therapy for the prevention of acute radiation dermatitis in head and neck cancer patients (DERMISHEAD trial). Radiother Oncol. 2021;158:268-75.
Ding PN, Lord SJ, Gebski V, Links M, Bray V, Gralla RJ, et al
. Risk of treatment-related toxicities from EGFR tyrosine kinase inhibitors: A meta-analysis of clinical trials of gefitinib, erlotinib, and afatinib in advanced EGFR-mutated non-small cell lung cancer. J Thorac Oncol 2017;12:633-43.
Fox LP. Nail toxicity associated with epidermal growth factor receptor inhibitor therapy. J Am Acad Dermatol 2007;56:460-5.
Liao BC, Lin CC, Yang JC. Second and third-generation epidermal growth factor receptor tyrosine kinase inhibitors in advanced nonsmall cell lung cancer. Curr Opin Oncol 2015;27:94-101.
Beshay A, Petersen M, Rhoads JLW. Severe EGFR inhibitor-induced acneiform eruption responding to dapsone. Dermatol Online J 2021;27(7).
Melosky B, Leighl NB, Rothenstein J, Sangha R, Stewart D, Papp K. Management of egfrtki-induced dermatologic adverse events. Curr Oncol 2015;22:123-32.
Segaert S, Tabernero J, Chosidow O, Dirschka T, Elsner J, Mancini L, et al
. The management of skin reactions in cancer patients receiving epidermal growth factor receptor targeted therapies. J Dtsch Dermatol Ges 2005;3:599-606.
[Figure 1], [Figure 2], [Figure 3]